5 results about "Epileptogenesis" patented technology

The invention provides application of OPC-like cell detection in prediction of glioblastoma with epilepsy. Specifically, the invention provides an application of a detection reagent of OPC-like cell markers PDGFRA and EGFRvIII in prediction of epilepsy of people with glioblastoma. The invention has an application prospect in the field of diagnosis and treatment of diseases of glioblastoma with epilepsy.

The subject matter of the present invention is the use of 2-Pentadecyl-2-oxazoline (also known as PEA-OXA) in association with butyric acid, in acidic or salified form, in the treatment of epilepsy and associated psychiatric comorbidities (such as social isolation). In particular, the present invention relates to PEA-OXA for use, in humans and animals, in the prevention and treatment of epileptogenesis and comorbidities associated with epilepsy, such as limited social interaction, wherein PEA-OXA is administered in association or in combination with butyric acid or a salt thereof, wherein said administration is separate, joint, or simultaneous.

The invention relates to the technical field of biological medicine, and discloses an application of biomarkers in preparation of a product for predicting epilepsy, the biomarkers are CXCL17 and GPR35, and a detection result is related to the combined expression level of CXCL17 and GPR35 in a biological sample. The invention further discloses a kit for assisting in predicting epilepsy occurrence and monitoring the drug treatment effect. The invention provides a product capable of applying the combined expression level of CXCL17 and GPR35 for the first time, the product can carry out rapid, objective, high-sensitivity and high-specificity prediction in the early stage of epilepsy occurrence, and after definite diagnosis of epilepsy, by monitoring the compensatory increase of CXCL17 and GPR35 in the chronic stage, the epilepsy can be quickly and objectively predicted in a high-sensitivity and high-specificity manner. The invention discloses an important role in an epilepsy nerve protection mechanism as a protective molecule.

The invention provides application of KCND2 detection in prediction of glioblastoma with epilepsy. Specifically, the invention provides application of KCND2 and a detection reagent thereof in predicting epilepsy of people with glioblastoma. The invention further provides a mouse model constructed by using the xenotransplantation KCND2 overexpressed patient-derived primary GBM tumor cells, and the mouse model can be used for further researching a mechanism of GBM with epilepsy and screening therapeutic drugs. The invention has an application prospect in the field of diagnosis and treatment of diseases of glioblastoma with epilepsy.

The invention provides an application of targeted KCND2 in prevention or treatment of glioblastoma with epilepsy. Specifically, the invention provides an application of a KCND2 inhibitor in preventing and / or treating epilepsy of a patient with glioblastoma. The invention also provides a pharmaceutical composition containing the KCND2 inhibitor and a method for preventing and / or treating epilepsy of a patient with glioblastoma by using the pharmaceutical composition. The invention has an application prospect in the field of treatment of diseases of glioblastoma with epilepsy.